Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C] Mass Balance Study of TY-9591 in Healthy Chinese Males
NCT05871905Phase 1Completed
- Sponsor
- TYK Medicines
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Primary endpoint: Total radioactivity in whole blood and plasma. Started Jun 2023; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05871905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871905.